After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. The Danish pharma giant ...

Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a ...

Obesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) have found themselves in two contrasting positions as Robert F. Kennedy Jr., a leading critic of weight loss drugs, takes the helm of ...

(Bloomberg) -- Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat products underscored the challenge to its weight-loss ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force behind its strong numbers. It may not be long before Novo Nordisk also ...

Lone Star has told Novo Banco SA to begin the initial public offering of shares in the Portuguese lender, which may be the country’s first major stock market listing in four years. “Novo Banco ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and weight loss drug participated in unlawful business practices. The ...

Novo Nordisk’s blockbuster weight-loss therapy semaglutide—sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management—could potentially help people curb their cravings for and ...

There’s a war of words brewing in the world of GLP-1s. Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has called the company to ...